128 patents currently held
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9 more records may belong here and await a decision; they are not counted.
The next term ends in May 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
May 2029
Next term end
66
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2034 · High confidence
Also notable
Ends May 2029 · Medium confidence
Also notable
Ends Dec 2033 · High confidence
Aryl- or Heteroaryl-Substituted Benzene Compounds
US 8,410,088
The most cited patent in this portfolio, cited by 138 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2034.
Inhibitors of Human EZH2, and Methods of Use Thereof
US 9,175,331
Cited by 95 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
PRMT5 Inhibitors and Uses Thereof
US 8,993,555
Cited by 83 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 5 fees due Dec 2 to 27, 2026 · next Dec 2
- 2 fees due Jan 28, 2027
- 3 fees due Feb 4 to 27, 2027 · next Feb 4
- 6 fees due Mar 1 to 29, 2027 · next Mar 1
- 2 fees due Apr 1 to 17, 2027 · next Apr 1
- 3 fees due May 3 to 5, 2027 · next May 3
- 4 fees due Jun 3 to 29, 2027 · next Jun 3
- 2 fees due Jul 7 to 26, 2027 · next Jul 7
- 1 fee due Aug 23, 2027The maintenance fee for PRMT5 Inhibitors and Uses Thereof (US 9,266,836) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 3, 2027The maintenance fee for Substituted Piperidine Compounds (US 10,577,363) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 5 fees due Oct 9 to 28, 2027 · next Oct 9
- 2 fees due Nov 10, 2027
Recent changes
- 4 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 66 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Aryl- or Heteroaryl-Substituted Benzene Compounds | 12 in force | to Aug 2034 |
| Salt Form of a Human Histone Methyltransferase EZH2 Inhibitor | 6 in force | to Apr 2033 |
| Inhibitors of Human EZH2 and Methods of Use Thereof | 6 in force | to Nov 2031 |
| PRMT5 Inhibitors and Uses Thereof | 5 in force | to Dec 2033 |
| PRMT1 Inhibitors and Uses Thereof | 4 in force | to Mar 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,175,331 | Inhibitors of Human EZH2, and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,333,217 | Inhibitors of Human EZH2, and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,334,527 | Inhibitors of Human EZH2, and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,949,999 | Inhibitors of Human EZH2, and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,691,507 | Inhibitors of Human EZH2 and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,895,245 | Inhibitors of Human EZH2 and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,096,634 | Substituted Purine and 7-Deazapurine Compounds In force · High confidence | In force | High confidence | |
| US 9,029,343 | Modulators of Histone Methyltransferase, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 9,145,438 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,962,620 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 128: 6 patents in force now held by others · 26 patents ended · 13 applications pending · 171 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.